Table 2.
Results of prospective, phase II trials evaluating allogeneic hematopoietic cell transplantation after reduced intensity conditioning.
| Author (Year) | Number of patients | Age (range) | Conditioning regimen | TRM | EFS/PFS | OS | Comments |
|---|---|---|---|---|---|---|---|
| Khouri et al. [48, 52] (2008 and 2012) | 47 | 53 (33–68) |
FCR +/− ATG | 15% (5 years) |
72% (11 years) |
78% (11 years) |
Grades 2–4 acute GVHD in 11%. All had chemosensitive disease. High-dose rituximab (1000 mg/m2) used. |
|
| |||||||
| Thomson et al. [49] (2010) | 82 | 45 (26–65) |
FMC | 15% (4 years) |
76% (4 years) |
76% (4 years) |
Grades 2–4 acute GVHD in 13%. Included 26% with prior auto-HCT and 9% with refractory disease. |
|
| |||||||
| Piana et al. [50] (2010) | 37 | 50 (34–62) |
FM | 35%* | 57% (4 years) |
54% (4 years) |
Grades 2–4 acute GVHD in 47%. Included 46% with prior auto-HCT. |
|
| |||||||
| Shea et al. [51] (2011) | 44 (16 had FL) |
53 (39–68) |
FC | 9% (3 years) |
75% (3 years) |
81% (3 years) |
All were sibling donors and none had prior auto-HCT. |
Abbreviations: FL: follicular lymphoma; FCR: fludarabine, cyclophosphamide, rituximab; ATG: antithymocyte globulin; F: fludarabine, M: melphalan, C: campath; FC: fludarabine, cyclophosphamide; TRM: treatment-related mortality; EFS/PFS: event/progression-free survival; OS: overall survival; GVHD: graft versus host disease; auto-HCT: autologous hematopoietic cell transplantation. *TRM estimated from numbers in the publication.